The firm recently won $4.5 million as well as approval for its Fertilome test from New York state, though some have questioned the test's clinical utility.
The award is one of 121 for projects in New York City this year, totaling $64.8 million.
The company has contracted with a urologist, who will review customers' requests for tests, and prescribe the firm's epigenetics-based male fertility analysis.
The companies will recruit and track a cohort of women to study environmental, genetic, and lifestyle factors that may contribute to fertility outcomes.
Celmatix's Fertilome test aims to give women genetic insight into their fertility.
Trial studying the use of next-generation sequencing-based pre-implantation genetic screening has its first birth, the Guardian reports.
Loci identified in a genome-wide association study of women with spontaneous fraternal twin birth offers clues to the hormonal processes behind this propensity.
The test uses Illumina arrays to measure genome-wide sperm DNA methylation patterns in order to predict male fertility status and resulting embryo quality.
They will work to accelerate the launch of Celmatix's infertility genetics tests and develop early screening tests for declining ovarian function.
Researchers have found an accumulation of mutations in the genome of the African cheetah that may contribute to its low reproductive success.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.